Table 2 Oncologic and survival outcomes of screen-detected and non-screen-detected T1 colorectal cancer (CRC) patients after 3 and 5 years.
| Screen detected (n = 1114) | Non-screen detected (n = 689) | Hazard ratio (95%CI) b | P value† | |||
| Event-free* at: | Event-free* at: | |||||
| 3 years, % (95%CI) | 5 years, % (95%CI) | 3 years, % (95%CI) a | 5 years, % (95%CI) | |||
| * Kaplan–Meier method estimates of the percentage of patients without the event of interest at 3 and 5 years, with corresponding 95%CI. † Hazard ratio and P value from multivariable Cox proportional hazards regression model, adjusted for polyp location, treatment strategy, differentiation grade, lymphovascular invasion, and resection margin (for TTR, MFS, and CSS) or age at diagnosis, sex and American Society of Anesthesiology classification (for overall survival). | ||||||
| Time to recurrence (TTS) | 98.4 (97.6–99.2) | 95.4 (93.7–97.0) | 98.0 (96.8–99.1) | 95.3 (93.3–97.4) | 1.05 (0.62–1.78) | 0.85 |
| Metastasis-free survival (MFS) | 98.7 (98.0–99.4) | 95.8 (94.2–97.4) | 98.8 (97.9–99.7) | 96.7 (94.9–98.5) | 1.41 (0.75–2.65) | 0.28 |
| Cancer-specific survival (CSS) | 99.3 (98.7–99.8) | 98.0 (96.9–99.1) | 99.0 (98.2–99.8) | 97.6 (96.1–99.0) | 1.05 (0.47–2.34) | 0.91 |
| Overall survival | 97.0 (95.9–98.1) | 91.9 (89.9–94.0) | 87.4 (84.8–90.0) | 75.3 (71.4–79.3) | 0.51 (0.38–0.68) | <0.001 |